Why the study?
Does the angiotensin I-converting enzyme gene insertion/deletion polymorphism affect the development, progression, or treatment response in renal diseases?
Does the angiotensin I-converting enzyme gene insertion/deletion polymorphism affect the development, progression, or treatment response in renal diseases?
The ACE gene insertion/deletion polymorphism influences the progression of renal diseases and the therapeutic response to ACE inhibitors, highlighting a genetic component in renal disease management.
No takes yet. Share an insight, caveat, or question.
May inform risk stratification in progressive renal disease; leaves open whether genotyping should guide ACE inhibitor use.
Schmidt et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: